MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R./S.1: Tax Cuts and Jobs Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CLAIRE WILLIS BRANDEWIE | — |
| JOSEPH M GANLEY | — |
| PETER SLONE | — |
Health Issues HCR
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CLAIRE WILLIS BRANDEWIE | — |
| JOSEPH M GANLEY | — |
| PETER SLONE | — |
Medicare/Medicaid MMM
Physician and pharmacy reimbursement issues; Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms; Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CLAIRE WILLIS BRANDEWIE | — |
| JOSEPH M GANLEY | — |
| BEN JONES | — |
| KATIE JONES | — |
| LISA LANGENDERFER | — |
| PETER SLONE | — |
Pharmacy PHA
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CLAIRE WILLIS BRANDEWIE | — |
| JOSEPH M GANLEY | — |
| BEN JONES | — |
| KATIE JONES | — |
| LISA LANGENDERFER | — |
| PETER SLONE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.